Roche Pays $100 Million for an RNA Drug That Targets Belly Fat, Not Appetite

Roche has bought an experimental obesity drug from China’s Rona Therapeutics, paying $100 million for full ownership, with milestone payments that could take the total to just over $1 billion, plus royalties. The drug uses RNA interference (RNAi) to switch off a gene called ALK7 in fat tissue. Unlike today’s blockbuster weight-loss medicines, it is not designed to reduce appetite.

What ALK7 does

ALK7 is a receptor on the surface of fat cells that helps regulate how they store and release fat. When it is active, it tells fat cells to hold on to their contents. The interest in it comes from human genetics: people who naturally carry variants that reduce ALK7 activity tend to have less fat around the abdomen, a healthier distribution of body fat, and a lower risk of type 2 diabetes. Silencing the gene with a drug is an attempt to copy that natural advantage.

How an RNAi drug works

Genes make proteins by first producing messenger RNA. An RNAi drug is a short piece of synthetic RNA, called siRNA, that finds and destroys a specific messenger RNA, so the protein is never made. The effect lasts for months, which is why approved RNAi medicines, such as the cholesterol drug inclisiran, are injected only twice a year. Until recently, RNAi drugs could reliably reach only the liver. Getting them into fat tissue is a newer technical advance, and it is what makes ALK7 a practical target.

Why this is different from GLP-1 drugs

Drugs such as Wegovy and Zepbound work mainly on the brain and gut, making people feel full so they eat less. They are highly effective, but they cause nausea and other digestive side effects, a meaningful share of the weight lost is muscle rather than fat, and weight tends to return when treatment stops. An ALK7 drug takes a different route, acting directly on fat cells to release stored fat. Its appeal is the possibility of reducing visceral fat, the harmful fat around the organs, with infrequent dosing and without appetite-related side effects.

A partner, not a replacement

No one expects an ALK7 drug alone to match the 15% to 25% weight loss seen with the leading injections. The more likely role is as a companion: added to a GLP-1 drug to shift weight loss toward fat and away from muscle, or used afterwards to help maintain weight loss with a few injections a year. Rona says its drug could be combined with incretin therapies. That fits a broader shift in the industry, away from simply chasing bigger numbers on the scale and toward the quality and durability of weight loss.

A suddenly crowded target

Roche is not alone. Alnylam and Arrowhead, the two leading RNAi specialists, have each taken an ALK7 drug into Phase 1 trials. GSK licensed an ALK7-targeting drug from another Chinese company, SiranBio, earlier in 2026, and Wave Life Sciences is developing an RNAi obesity medicine aimed at the same pathway. Several large companies converging on one target within a year suggests they find the genetic evidence persuasive — and that being first, or best, will matter.

Roche’s obesity ambitions

Roche arrived late to the obesity market and has been buying its way in. It acquired Carmot Therapeutics in 2023, gaining three incretin-based drugs, and later struck a licensing deal with Zealand Pharma for an amylin-based candidate that may prove easier to tolerate than existing medicines. With the Rona drug it now has six experimental obesity medicines spanning several mechanisms, which would allow it to test combinations entirely within its own pipeline.

Another deal in China

The agreement is Roche’s fifth with a China-based drugmaker since late August and its tenth since the start of 2025, more than any of its large peers, according to BioPharma Dive. Rona, founded in 2022 and backed by investors including Lilly Asia Ventures, built its platform in part on RNA technology licensed from Sanofi. Western companies increasingly source early-stage drugs from Chinese biotechs, which can move quickly and at lower cost.

The caveats

This is early-stage science. No human data for Rona’s drug have been reported, and its stage of development was not disclosed. Genetic evidence is a good guide to which targets are worth pursuing, but it does not guarantee that a drug will work: lifelong reduced activity of a gene is not the same as switching it off in adulthood. It is not yet known how much fat loss ALK7 silencing produces in people, where the released fat goes, or whether there are long-term effects on the liver or metabolism. Because RNAi effects last for months, any side effect would also be slow to reverse.

What it means

For patients, nothing changes soon; drugs like this are years from the market, if they succeed at all. But the deal shows where obesity medicine is heading: toward combinations that target appetite and fat tissue separately, with the goal of losing fat while keeping muscle, and of maintaining weight loss with far fewer injections. This is business news, not investment or medical advice.